Literature DB >> 11898575

Is the promise of randomized control trials ("evidence-based medicine") overstated?

Louis R Caplan1.   

Abstract

Mesh：

Year:  2002        PMID： 11898575     DOI： 10.1007/s11910-002-0044-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  41 in total

1.  How do observational studies expand the evidence base for therapy?

Authors:  M J Radford; J M Foody
Journal:  JAMA       Date:  2001-09-12       Impact factor: 56.272

2.  Evidence based medicine: concerns of a clinical neurologist.

Authors:  L R Caplan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

3.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.

Authors:  Jan van Gijn; Ale Algra; Jaap Kappelle; Peter J Koudstaal; Anet van Latum
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

7.  Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.

Authors:  H P Adams; T G Brott; A J Furlan; C R Gomez; J Grotta; C M Helgason; T Kwiatkowski; P D Lyden; J R Marler; J Torner; W Feinberg; M Mayberg; W Thies
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

8.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

9.  The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group.

Authors: 
Journal:  Lancet       Date:  1987-12-12       Impact factor: 79.321

10.  A randomized trial of aspirin and sulfinpyrazone in patients with TIA.

Authors:  L Candelise; G Landi; P Perrone; M Bracchi; G Brambilla
Journal:  Stroke       Date:  1982 Mar-Apr       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.